RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+1.73%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.85B
AUM Growth
+$6.85B
(+3.3%)
Cap. Flow
+$642M
Cap. Flow
% of AUM
9.38%
Top 10 Holdings %
Top 10 Hldgs %
38.32%
Holding
136
New
16
Increased
27
Reduced
15
Closed
12
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$115M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$94.1M |
| 3 |
Penumbra
PEN
|
$67.7M |
| 4 |
argenx
ARGX
|
$62M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$52.9M |
Top Sells
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$153M |
| 2 |
InMode
INMD
|
$19.9M |
| 3 |
IDEAYA Biosciences
IDYA
|
$17.6M |
| 4 |
Guardant Health
GH
|
$11.2M |
| 5 |
AGEN
Agenus
AGEN
|
$10.3M |
Sector Composition
| 1 | Healthcare | 93.33% |
| 2 | Financials | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Protagonist Therapeutics
PTGX
$3.62B
| $88.9M | 1.3% |
2,599,822
+846,127
| +48% | +$28.9M |
|
27
Stoke Therapeutics
STOK
$1.08B
| $87.4M | 1.28% |
3,644,248
| – | – |
|
|
28
Guardant Health
GH
$8.11B
| $81.4M | 1.19% |
813,342
-112,000
| -12% | -$11.2M |
|
29
C4 Therapeutics
CCCC
$182M
| $80.3M | 1.17% |
2,494,965
| – | – |
|
30
PMV Pharmaceuticals
PMVP
$82.1M
| $68.9M | 1.01% |
2,980,960
+2,171,097
| +268% | +$50.2M |
|
31
Fulcrum Therapeutics
FULC
$353M
| $68.4M | 1% |
3,866,872
+11,581
| +0.3% | +$205K |
|
32
MacroGenics
MGNX
$121M
| $63.8M | 0.93% |
3,975,554
| – | – |
|
33
Axsome Therapeutics
AXSM
$6.09B
| $61.2M | 0.89% |
1,618,819
+2,322
| +0.1% | +$87.7K |
|
34
Regenxbio
RGNX
$498M
| $60.3M | 0.88% |
1,845,366
| – | – |
|
|
35
IDEAYA Biosciences
IDYA
$2.26B
| $59.6M | 0.87% |
2,520,076
-746,179
| -23% | -$17.6M |
|
|
CUTR
36
DELISTED
Cutera, Inc.
CUTR
| $57.7M | 0.84% |
1,397,063
+139,201
| +11% | +$5.75M |
|
37
ProQR Therapeutics
PRQR
$256M
| $56.3M | 0.82% |
7,027,725
+584,612
| +9% | +$4.68M |
|
|
BCYC
38
Bicycle Therapeutics
BCYC
$492M
| $52.9M | 0.77% |
+869,271
| New | +$52.9M |
|
39
Adicet Bio
ACET
$60.8M
| $52.9M | 0.77% |
+3,023,744
| New | +$52.9M |
|
40
Sarepta Therapeutics
SRPT
$1.98B
| $52.4M | 0.77% |
+582,265
| New | +$52.4M |
|
41
GH Research
GHRS
$870M
| $50.6M | 0.74% |
2,168,957
| – | – |
|
|
SNCE
42
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $49.6M | 0.72% |
3,975,000
+3,000,000
| +308% | +$37.4M |
|
|
DMTK
43
DELISTED
DermTech, Inc. Common Stock
DMTK
| $49.3M | 0.72% |
3,118,666
+1
| +0% | +$16 |
|
44
Relmada Therapeutics
RLMD
$48.8M
| $49.3M | 0.72% |
2,186,324
+648,298
| +42% | +$14.6M |
|
|
BLU
45
DELISTED
BELLUS Health Inc.
BLU
| $48M | 0.7% |
5,968,017
+1,000,000
| +20% | +$8.05M |
|
46
Tenaya Therapeutics
TNYA
$192M
| $46.6M | 0.68% |
2,458,750
| – | – |
|
|
AVDL
47
Avadel Pharmaceuticals
AVDL
$1.42B
| $46.4M | 0.68% |
5,741,939
| – | – |
|
48
Tarsus Pharmaceuticals
TARS
$2.44B
| $45.3M | 0.66% |
2,013,601
| – | – |
|
49
Apyx Medical
APYX
$71.9M
| $43.6M | 0.64% |
3,398,279
| – | – |
|
50
Immunocore
IMCR
$1.78B
| $42.6M | 0.62% |
1,245,532
| – | – |
|